Drug Profile
Research programme: bispecific antibodies - Genmab/Novo Nordisk
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified